BCAL Diagnostics Limited (BDX) AI Stock Analysis

• Market Cap: AU$28.55M
• Dividend Yield: N/A
• Average Volume (3M): 266.88K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: N/A
• EPS Growth: -17.26%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 56
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 365,967,900
• 10 Day Avg. Volume: 153,498
• 30 Day Avg. Volume: 266,881
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

BCAL Diagnostics Limited faces significant challenges, with persistent losses and negative cash flows impacting financial performance. Technical indicators suggest a bearish trend, while valuation metrics reflect ongoing profitability issues. The company needs strategic improvements to enhance its financial health and investor appeal.

BCAL Diagnostics Limited Business Overview & Revenue Model

Company Description

BCAL Diagnostics Limited (BDX) is a biotechnology company focused on developing innovative diagnostic solutions for the healthcare sector. The company's core product is a non-invasive blood test designed to detect breast cancer in its early stages, offering a promising alternative to traditional mammogram screening methods. BCAL Diagnostics aims to improve patient outcomes through early detection and intervention, leveraging advanced scientific research and technology.

How the Company Makes Money

BCAL Diagnostics Limited generates revenue primarily by developing and commercializing its proprietary diagnostic tests. The company monetizes its technology through partnerships with healthcare providers, hospitals, and diagnostic labs that utilize its blood tests for early breast cancer detection. Additionally, BCAL may earn revenue from licensing its technology to other biotech firms or healthcare organizations, enabling broader distribution and application of its diagnostic solutions. The company might also engage in collaborative research and development partnerships that provide funding and resource sharing opportunities, contributing to its financial performance.

BCAL Diagnostics Limited Financial Statement Overview

Summary

BCAL Diagnostics Limited is experiencing revenue growth but continues to struggle with profitability and cash flow management. The low leverage provides some financial stability, yet persistent losses and negative cash flows present significant challenges. Strategic improvements are needed to enhance operational efficiency and financial performance.

Income Statement

The company showed a modest revenue growth of 8.59% from 2023 to 2024, but continues to face significant profitability challenges. The gross profit margin remains positive, but both EBIT and EBITDA margins are negative, indicating operational inefficiencies. The net profit margin is also negative, reflecting ongoing losses.

Balance Sheet

The balance sheet shows a relatively stable equity position with a debt-to-equity ratio of 0.18, suggesting low leverage. However, the equity ratio of 70.05% indicates a reliance on equity financing. The return on equity is negative due to net losses, highlighting a lack of profitability.

Cash Flow

Cash flows are under pressure with negative operating and free cash flows. The free cash flow growth rate improved slightly but remains negative. The operating cash flow to net income ratio is not favorable, indicating challenges in converting income into cash.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
3.10M	2.85M	718.67K	275.25K	442.10K
	Gross Profit
3.10M	2.74M	698.06K	275.25K	434.37K
	EBIT
-5.45M	-7.90M	-4.10M	-1.80M	-1.14M
	EBITDA
-5.67M	-7.72M	-4.06M	-1.80M	-1.03M
	Net Income Common Stockholders
-6.40M	-5.06M	-3.39M	-1.52M	-696.36K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.47M	3.17M	9.57M	3.41M	416.23K
	Total Assets
12.27M	8.37M	10.59M	4.13M	819.55K
	Total Debt
1.52M	1.06M	0.00	0.00	300.00K
	Net Debt
-4.95M	-2.11M	-5.57M	-3.41M	-116.22K
	Total Liabilities
3.68M	3.16M	950.42K	525.60K	380.64K
	Stockholders Equity
8.59M	5.21M	9.64M	3.61M	438.92K
Cash Flow		Free Cash Flow
-5.67M	-6.41M	-7.25M	-1.21M	-665.46K
	Operating Cash Flow
-4.52M	-6.05M	-3.22M	-1.21M	-661.65K
	Investing Cash Flow
-1.15M	3.64M	-4.03M	-3.85K	-3.81K
	Financing Cash Flow
8.97M	13.24K	9.41M	4.20M	805.04K

BCAL Diagnostics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BDX, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.45 is Neutral, neither overbought nor oversold. The STOCH value of 16.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BDX.

BCAL Diagnostics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGS	75 Outperform	$230.43M	20.77	17.87%	―	18.30%	35.70%
RHT	64 Neutral	AU$16.55M	140.00	-3.11%	―	89.13%	69.57%
Sector *	52 Neutral	$5.35B	3.81	-42.57%	2.86%	17.10%	1.33%
IPD	51 Neutral	$79.07M	―	-51.08%	―	10.22%	-2.94%
GTG	43 Neutral	$9.45M	―	-181.97%	―	-11.76%	22.83%
BDX	42 Neutral	AU$28.55M	―	-104.23%	―	―	-17.26%
CDX	36 Underperform	$21.88M	―	-467.81%	―	-75.71%	-8.26%

BCAL Diagnostics Limited Corporate Events

BCAL Diagnostics Launches Innovative Breast Cancer Blood Test

BCAL Diagnostics Limited has launched its first-in-class blood test, BREASTEST plus, which achieved its first revenues in March 2025. This launch represents a significant milestone in breast cancer diagnostics, particularly for women with dense breasts where traditional imaging is less effective. The company is expanding its market access and clinician engagement strategies in Australia, with plans for a national rollout, while also laying the groundwork for US market entry. BCAL continues to strengthen its patent portfolio and maintain a solid financial position with a cash balance of $5 million, focusing on efficient resource deployment to achieve its strategic objectives.

BCAL Diagnostics Advances Breast Cancer Screening with Non-Invasive Blood Test

BCAL Diagnostics Limited has announced advancements in breast cancer screening technology with their non-invasive blood test. This development could significantly impact the company’s operations by positioning it as a leader in the diagnostic industry, potentially benefiting stakeholders through improved screening methods and early detection capabilities.

BCAL Diagnostics Launches Groundbreaking Breast Cancer Test

BCAL Diagnostics Limited has announced the commercial launch of BREASTEST plus, a first-in-class blood test for breast cancer diagnostics, marking the company’s first revenue generation. This innovative test addresses the challenge of high breast density, which affects a significant portion of women in breast cancer screening programs, and is set to be rolled out initially in Sydney and Melbourne. The launch is supported by additional patent grants, securing intellectual property protection for the technology until 2043, and positions BCAL at the forefront of blood-based breast cancer detection, potentially improving early detection and reducing unnecessary follow-ups.

BCAL Diagnostics Reports Increased Losses Amidst Strategic Expansion

BCAL Diagnostics Limited reported a significant decrease in revenue by 26% and an increased net loss of 66% for the half-year ending December 31, 2024, compared to the previous year. Despite the financial challenges, the company expanded its operations by incorporating a wholly owned subsidiary in North Carolina, USA, indicating a strategic move to enhance its market presence.